Announcement on Subsidiary Companies Obtaining Drug Registration Approval
Release time:
2020-08-05
Securities Code: 600668 Securities Abbreviation: Sharp Group No.: Pro 2019-007
Bond Abbreviation: 13 Spike 02 Bond Code: 122344
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Registration Approval
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and shall bear individual and joint liability for the authenticity, accuracy and completeness of its contents.
Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "Jianfeng Pharmaceutical"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Registration Approval Document" (Approval No.: 2019S00296) of olopatadine hydrochloride eye drops approved and issued by the State Drug Administration. The relevant information is hereby announced as follows: basic Information of
1. Drugs
Drug Name: Olopatadine Hydrochloride Eye Drops
Dosage Form: Ophthalmic Preparation
Specification: 0.1 (5ml:5mg, based on C 21 H 23 NO 3 )
Application Items: Domestic Drug Registration
Registration Classification: Chemical Drug Class 4
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Acceptance Number: CYHS1600042 Zhejiang
batch number: 2019S00296
drug standard number: YBH00792019
drug validity period: 36 months
drug approval number: national drug H20193095
drug approval number validity period: until April 02, 2024
approval conclusion: according to the "the People's Republic of China Drug Administration Law" and relevant regulations, after examination, this product meets the relevant requirements of drug registration, approves the registration, and issues the drug approval number.
Other relevant conditions of 2. drug
This drug is used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1- receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments.
Olopatadine Hydrochloride Eye Drops has been included in the National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition) and classified as Class B; it is not included in the National Essential Drugs List (2018 Edition). At present, Novartis Europharm Limited, towering pharmaceutical (China) co., ltd., Jiangsu hanchen pharmaceutical co., ltd., Jiangxi kelun pharmaceutical co., ltd., Guangdong hongying technology co., ltd., Qilu pharmaceutical co., ltd. and Shenyang xingqi ophthalmic co., ltd. olopatadine hydrochloride eye drops have been approved for listing in China. After querying the IMS database, global sales of olopatadine hydrochloride eye drops in 2018 were approximately US $0.37 billion and China sales were approximately US $10.232 million.
Up to now, the research and development investment of spiking pharmaceutical olopatadine hydrochloride eye drops project is about 660 yuan. The impact of
3. on the company
Jianfeng Pharmaceutical already has a corresponding production line. This time, it has obtained the Drug Registration Approval Document of olopatadine hydrochloride eye drops, which indicates that Jianfeng Pharmaceutical has the qualification to produce and sell the drug. It will further enrich the product line of Jianfeng Pharmaceutical and help to enhance the competitiveness of the company's pharmaceutical business.
4. Risk Warning
Company attaches great importance to the quality and safety of drug research and development, manufacturing and sales. However, due to the characteristics of high technology, high risk and high added value of pharmaceutical products, not only the early stage of drug research and development, approval to production has a long cycle, large investment and many links, moreover, the production and sales of drugs after obtaining approval are also vulnerable to national policies, market environment and other factors. Please the majority of investors cautious decision-making, pay attention to prevent investment risk.
Zhejiang Jianfeng Group Co., Ltd.
Board of Directors
April 17, 2019
More information
Tianjin Flemish Company Donates Anti-epidemic Materials
On the morning of July 13, Tianjin Jianfeng Flanders Pharmaceutical Technology Development Co., Ltd. donated materials to the Tianjin Development Zone Charity Association to help the development zone community fight the epidemic.
2020
08-05
In late July, leaders of the group company Jiang Xiaomeng, Yu Jianhong, Chen Tianci and Qin Xuping visited subordinate enterprises separately and sent heatstroke prevention and cooling supplies to employees working under high temperature, urging everyone to pay attention to heatstroke prevention and cooling and safe production work to ensure good physical condition.
2020
08-05
On July 17 and 18, the Group's work analysis meeting for the first half of 2020 was held at the Peak Building of the Group's headquarters to summarize and review the work in the first half of the year and make arrangements for the work in the second half of the year.
2020
08-05
The company requires to do a good job in summer safety production
The high temperature season is approaching, and the group company issued a notice a few days ago to make arrangements for safe production in summer.
2020
08-05
The company requires to do a good job in summer safety production
The high temperature season is approaching, and the group company issued a notice a few days ago to make arrangements for safe production in summer. The notice requires all subordinate units of the company to attach great importance to the work of production safety in summer, and all production and business units should hold a special meeting on production safety in summer. According to the characteristics of production in summer, they should focus on safety risk analysis for mines, outdoor operations and high-temperature posts, and implement control measures to avoid the occurrence of safety accidents such as scalding, heatstroke and electric shock. In order to further strengthen the safety production management in the high temperature season, the notice requires the main person in charge of each production and business unit to lead a team to conduct a comprehensive inspection of the production and business premises according to the characteristics of summer production; strengthen the daily safety production inspection of key posts and special posts; timely rectify the found unsafe behaviors and hidden dangers; Strengthen the management of the storage and use of flammable, explosive, dangerous chemicals and drugs; cooling measures shall be taken for the space exceeding the storage temperature limit of articles. If it is found that the electrical equipment circuit and exhaust fan circuit are aged and damaged, replace them in time and keep the grounding wire in good condition. Do a good job in checking the fire pool, pipeline water pressure and fire extinguishing equipment to ensure that the fire fighting facilities are sensitive, intact and reliable. The high temperature in summer is also a period of frequent occurrence of heatstroke and other diseases. The notice requires all units to do a good job in heatstroke prevention and cooling, implement various relevant measures, and equip necessary cooling facilities or materials such as fans, air conditioners, ice cubes and other cooling facilities or materials according to the conditions of the production site; do a good job in the distribution of heatstroke prevention drugs, supplies and cool drinks in workshops, warehouses, construction sites and other production lines; strengthen canteen management to prevent food poisoning. (this newspaper reporter)
2020
07-22
The company requires to do a good job in summer safety production
The high temperature season is approaching, and the group company issued a notice a few days ago to make arrangements for safe production in summer. The notice requires all subordinate units of the company to attach great importance to the work of production safety in summer, and all production and business units should hold a special meeting on production safety in summer. According to the characteristics of production in summer, they should focus on safety risk analysis for mines, outdoor operations and high-temperature posts, and implement control measures to avoid the occurrence of safety accidents such as scalding, heatstroke and electric shock. In order to further strengthen the safety production management in the high temperature season, the notice requires the main person in charge of each production and business unit to lead a team to conduct a comprehensive inspection of the production and business premises according to the characteristics of summer production; strengthen the daily safety production inspection of key posts and special posts; timely rectify the found unsafe behaviors and hidden dangers; Strengthen the management of the storage and use of flammable, explosive, dangerous chemicals and drugs; cooling measures shall be taken for the space exceeding the storage temperature limit of articles. If it is found that the electrical equipment circuit and exhaust fan circuit are aged and damaged, replace them in time and keep the grounding wire in good condition. Do a good job in checking the fire pool, pipeline water pressure and fire extinguishing equipment to ensure that the fire fighting facilities are sensitive, intact and reliable. The high temperature in summer is also a period of frequent occurrence of heatstroke and other diseases. The notice requires all units to do a good job in heatstroke prevention and cooling, implement various relevant measures, and equip necessary cooling facilities or materials such as fans, air conditioners, ice cubes and other cooling facilities or materials according to the conditions of the production site; do a good job in the distribution of heatstroke prevention drugs, supplies and cool drinks in workshops, warehouses, construction sites and other production lines; strengthen canteen management to prevent food poisoning. (this newspaper reporter)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page